Denver PWM’s CRISPR Therapeutics CRSP Stock Holding History

Denver PWM’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-838	Closed	-$45.3K	–	173
2024 Q2	$45.3K	Buy	+838	New	+$48.5K	0.02%	139

Other funds holding CRSP

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Denver PWM's CRSP Position: Q3 2024 in Review

Denver PWM sold out of CRISPR Therapeutics (CRSP) in Q3 2024, closing a stake of 838 shares — an estimated $45.3K sold.

Denver PWM first reported a position in CRSP in Q2 2024 and held it in 1 quarter. The position peaked at $45.3K in Q2 2024. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

Denver PWM reported no remaining CRISPR Therapeutics position as of Q3 2024 after selling out during the quarter.
Denver PWM sold 838 CRISPR Therapeutics shares in Q3 2024, an estimated $45.3K.
Denver PWM first reported a position in CRISPR Therapeutics in Q2 2024 and held it in 1 quarter.
Denver PWM's CRISPR Therapeutics position peaked at $45.3K in Q2 2024.
416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on Denver PWM's 13F filing for Q3 2024, filed 31 Oct 2024.